Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.78 USD 3.9% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Alkermes Plc?
Write Note

Alkermes Plc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Alkermes Plc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Alkermes Plc
NASDAQ:ALKS
Accounts Payable
$37m
CAGR 3-Years
0%
CAGR 5-Years
-15%
CAGR 10-Years
3%
Amarin Corporation PLC
NASDAQ:AMRN
Accounts Payable
$40.5m
CAGR 3-Years
-18%
CAGR 5-Years
-1%
CAGR 10-Years
21%
Prothena Corporation PLC
NASDAQ:PRTA
Accounts Payable
$10.3m
CAGR 3-Years
43%
CAGR 5-Years
34%
CAGR 10-Years
24%
No Stocks Found

Alkermes Plc
Glance View

Market Cap
4.7B USD
Industry
Biotechnology

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

ALKS Intrinsic Value
28.59 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Alkermes Plc's Accounts Payable?
Accounts Payable
37m USD

Based on the financial report for Sep 30, 2024, Alkermes Plc's Accounts Payable amounts to 37m USD.

What is Alkermes Plc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
3%

Over the last year, the Accounts Payable growth was -57%.

Back to Top